NCT02310568

POC Study in Partially Responsive Generalized Anxiety Disorder

An 8-week, Randomized, Phase 2, Double-blind, Sequential Parallel-group Comparison Study Of Two Dose Levels Of Pf 06372865 Compared To Placebo As An Adjunctive Treatment In Outpatients With Inadequate Response To Standard Of Care For Generalized Anxiety Disorder

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 90 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate whether PF-06372865 is safe and effective in the treatment of sub-optimally controlled symptoms of generalized anxiety disorder during two 4-week treatment periods using a Sequential Parallel Comparison Design (SPCD). The study will use the Hamilton Anxiety Rating Scale (HAM-A) to measure change in symptoms from baseline for two doses of PF-06372865 compared to placebo.

Conditions

• Generalized Anxiety Disorder

Interventions

Type	Name	Description
DRUG	PF-06372865.	Blinded PF 06372865 and matching placebo will be provided as tablets for oral administration.

Timeline

• Start date: 2014-11-01
• Primary completion: 2015-10-01
• Completion: 2015-10-01
• First posted: 2014-12-08
• Last updated: 2017-01-09
• Results posted: 2016-11-15

Locations

47 sites across 1 country: United States